Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Thatcher

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
BMC Proceedings|October 4, 2008
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global viewNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|July 21, 2004
Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introductionNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
The place of targeted therapy in the patient management of non-small cell lung cancerNicholas Thatcher
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
New drugs in small cell lung cancerNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Survival improvement in thoracic cancer: progress from the last decade and beyondChristian Manegold, Nicholas Thatcher
Lancet (London, England)|November 26, 2008
Gefitinib or docetaxel in advanced non-small-cell lung cancerMichael Cullen, Nicholas Thatcher
The Oncologist|October 9, 2010
Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancerNicholas Thatcher, Jim Heighway
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomicsNicholas Thatcher, Christian Manegold
Current Opinion in Oncology|March 7, 2002
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and durationRichard Booton, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|April 30, 2010
Gefitinib for the treatment of non-small-cell lung cancerLynn Campbell, Fiona Blackhall, Nicholas Thatcher
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
BMC Proceedings|October 4, 2008
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global viewNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|July 21, 2004
Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introductionNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
The place of targeted therapy in the patient management of non-small cell lung cancerNicholas Thatcher
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
New drugs in small cell lung cancerNicholas Thatcher
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Survival improvement in thoracic cancer: progress from the last decade and beyondChristian Manegold, Nicholas Thatcher
Lancet (London, England)|November 26, 2008
Gefitinib or docetaxel in advanced non-small-cell lung cancerMichael Cullen, Nicholas Thatcher
The Oncologist|October 9, 2010
Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancerNicholas Thatcher, Jim Heighway
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomicsNicholas Thatcher, Christian Manegold
Current Opinion in Oncology|March 7, 2002
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and durationRichard Booton, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|April 30, 2010
Gefitinib for the treatment of non-small-cell lung cancerLynn Campbell, Fiona Blackhall, Nicholas Thatcher
Pageof 4